BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells()

Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Xing, Jieyu, Lin, Limin, Li, Jing, Liu, Jiayu, Zhou, Changhua, Pan, Haitao, Shu, Rui, Dong, Bin, Cao, Donglin, Li, Qing, Wang, Zhong
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2017
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548338/
https://ncbi.nlm.nih.gov/pubmed/28797938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2017.07.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados